Enbridge Energy, L.P. (NYSE:EEP)
Enbridge Energy Partners, L.P. owns the U.S. portion of the world’s longest liquid petroleum pipeline. Enbridge Energy Company, Inc., an indirect wholly owned subsidiary of Enbridge Inc. of Calgary, Alberta, holds an effective 14.5% interest in the Partnership. (Press Release)
Enbridge Energy, L.P. (NYSE:EEP)’s Financial Overview
Enbridge Energy, L.P. (NYSE) declined -0.28% yesterday to close its trading session at $10.82. The company has 1 year Price Target of $11.92. Enbridge Energy, L.P. has 52-Week high of $15.56 and 52-Week Low of $8.89. The stock touched its 52-Week High on 15.56 and 52-Week Low on 8.89. The stock traded with the volume of 8.22 Million shares yesterday. The firm shows the market capitalization of $3.56 Billion.
Enbridge Energy, L.P. (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.19/share against the analyst consensus estimate of $0.15/share. The difference between the actual and expected EPS is $0.04 a share with a surprise factor of 26.7%.
The firm is trading with SMA20 of 0.21 Percent, SMA50 of -2.98 Percent and SMA200 of -2.55 percent. Enbridge Energy, L.P. has P/S value of 1.51 while its P/B value stands at 3.42. Similarly, the company has Return on Assets of 1.5 percent, Return on Equity of 14.4 percent and Return on Investment of 12.9 Percent. The company shows Gross Margin and Operating Margin of 88.1 percent and 42.8 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 3.1 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 8 analysts offering 12-month price forecasts for Enbridge Energy Partners LP have a median target of 12.00, with a high estimate of 16.00 and a low estimate of 11.00. The median estimate represents a +10.91% increase from the last price of 10.82.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)’s Financial Outlook
The 1 analysts offering 12-month price forecasts for Titan Pharmaceuticals Inc have a median target of 0.45, with a high estimate of 0.45 and a low estimate of 0.45. The median estimate represents a +7.14% increase from the last price of 0.42.
Titan Pharmaceuticals, Inc. is estimated to report earnings on 11/08/2018. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.13. The reported EPS for the same quarter last year was $-0.2.
According to Zacks Investment Research, Titan Pharmaceuticals, Inc. has a Consensus Recommendation of 0. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock declined -2.33% and closed its last trading session at $0.42. The company has the market capitalization of $22.21 Million. The stock has 52-week high of $1.9 and 52-Week low of $0.17. The firm touched its 52-Week high on 2.00 and 52-Week low on 0.17. The company has volume of 8.21 Million shares. The company has a total of 52.89 Million shares outstanding.
Titan Pharmaceuticals, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.04/share where the analyst estimated EPS was $-0.13/share. The difference between the actual and Estimated EPS is $0.09. This shows a surprise factor of 69.2 percent.
The company has YTD performance of -68.3 percent. Beta for Titan Pharmaceuticals, Inc. stands at -0.1 while its ATR (average true range) is 0.08. The company has Weekly Volatility of 21.86%% and Monthly Volatility of 23.32%%.
Titan Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of 24.27%, Distance from 50-Day Simple Moving Average of 2.36 percent and Distance from 200-Day Simple Moving Average of -49.34%.
The Company currently has ROA (Return on Assets) of -143.6 percent, Return on Equity (ROE) of 0 Percent and Return on Investment (ROI) of -193.4% with Gross margin of 98.2 percent and Operating & Profit margin of 0% and 0% respectively.